Skip Nav Destination
Issues
1 January 2009
-
Cover Image
Cover Image
The cover image is a photomicrograph (60X magnification) of immunocytochemical staining for estrogen receptor-β (ER-β) expression in cultured human HCT-116 colon cancer cells. Associated with colon carcinogenesis, ER-β expression is a potential target for colorectal cancer prevention and treatment. The receptor's expression in human colon cancer cells is highly localized in the nuclei (intense brownish, dark staining). Sporadic colorectal cancer models suggest that ER-β expression (protein and RNA) is selectively associated with cells of colorectal tumors but not normal-appearing epithelia. Furthermore, the selective estrogen-receptor modulator raloxifene suppressed human colon cancer cell growth in vitro and in chemically induced colon carcinogenesis in rats. These findings support the promise of ER-β as a target for colorectal cancer chemoprevention. See article by Janakiram et al. (beginning on page 52) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Letter from the Editor
Perspective
Different Perspective
Research Articles
Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients
Vassiliki Papadimitrakopoulou; Julie G. Izzo; Diane D. Liu; Jeffrey Myers; Tania L. Ceron; Jan Lewin; William N. William, Jr.; Anthea Atwell; J. Jack Lee; Ann Gillenwater; Adel El-Naggar; Xifeng Wu; Scott M. Lippman; Walter N. Hittelman; Waun Ki Hong
Growth Inhibition and Regression of Lung Tumors by Silibinin: Modulation of Angiogenesis by Macrophage-Associated Cytokines and Nuclear Factor-κB and Signal Transducers and Activators of Transcription 3
Alpna Tyagi; Rana P. Singh; Kumaraguruparan Ramasamy; Komal Raina; Elizabeth F. Redente; Lori D. Dwyer-Nield; Richard A. Radcliffe; Alvin M. Malkinson; Rajesh Agarwal
Letter to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.